Spironolactone for PCOS: Dosing, Monitoring, and Contraception
Spironolactone is an appropriate and effective treatment for androgenic symptoms in women with PCOS, but requires strict contraception due to teratogenic risk and regular monitoring for hyperkalemia.
Appropriateness and Efficacy
Spironolactone is a well-established option for treating hyperandrogenic manifestations in PCOS, particularly when hormonal contraceptives are contraindicated or not desired. Combined oral contraceptives (COCs) plus spironolactone is more effective than metformin alone for reducing hirsutism, with a mean difference of 4.6 points on the Ferriman-Gallwey score 1. However, spironolactone monotherapy shows no significant advantage over metformin for hirsutism reduction in PCOS women 2, making combination therapy preferable when possible.
The evidence shows spironolactone significantly improves hirsutism in idiopathic hirsutism but displays a more modest effect in PCOS populations 3. It does not improve metabolic parameters like HOMA-IR, BMI, or menstrual cyclicity 3.
Recommended Dosing
The standard dose is 100 mg daily, which has been most extensively studied 1. Lower doses of 50 mg daily show less robust effects 3. Some protocols allow titration up to 150 mg daily if tolerated 4. The mean effective dose in clinical trials is approximately 26-100 mg daily 5, 1.
Mandatory Contraception Requirements
Spironolactone is FDA Pregnancy Category X equivalent and must be avoided in pregnancy 5. The drug causes feminization of male fetuses in animal studies, with dose-dependent effects on reproductive tract development including decreased prostate and seminal vesicle weights 5.
All women of reproductive potential must use effective contraception while taking spironolactone. The most practical approach is combining spironolactone with COCs, which addresses both contraception and enhances anti-androgenic efficacy 1. If COCs are contraindicated, progestin-only pills or long-acting reversible contraception are acceptable alternatives 4.
Monitoring Protocol
Initial Monitoring
- Check serum potassium within 1 week of initiation or dose titration 5
- Baseline renal function (serum creatinine, creatinine clearance)
- Baseline electrolytes (potassium, sodium, magnesium, calcium)
- Blood pressure
Ongoing Monitoring
- Regular potassium monitoring throughout treatment 5
- More frequent monitoring if concurrent use of ACE inhibitors, ARBs, or other potassium-sparing agents 5
- Periodic renal function assessment 5
- Electrolyte panel every 3 months initially, then every 6 months if stable 5
Key Safety Considerations
Hyperkalemia risk is low in women with PCOS without kidney or heart disease when combined with hormonal contraception 4. In a study of 98 treatment periods, only mild hyperkalemia (5.1-5.5 mEq/L) occurred, with no severe cases 4. However, vigilance is required, particularly with:
- Impaired renal function (exclude if creatinine >2.5 mg/dL or baseline potassium >5.0 mEq/L) 5
- Concurrent nephrotoxic drugs 5
- Potassium supplements or salt substitutes 5
Common Side Effects
- Menstrual irregularities (most common) 2, 6
- Polyuria 2
- Gastrointestinal symptoms (nausea, vomiting, diarrhea) 3
- Gynecomastia in males (not relevant for PCOS) 5
- Rare: dose-dependent sinus tachycardia and palpitations, even in normotensive patients 6
Clinical Pitfalls to Avoid
- Never prescribe spironolactone without ensuring effective contraception - the teratogenic risk to male fetuses is real 5
- Do not use in women planning pregnancy - discontinue well before conception attempts 5
- Avoid in patients with baseline potassium >5.0 mEq/L or creatinine >2.5 mg/dL 5
- Do not combine with potassium supplements without very close monitoring 5
- Monitor for cardiac symptoms including palpitations, particularly at higher doses 6
Treatment Duration
Long-term use (≥12 months) is safe and well-tolerated in PCOS women without kidney or heart disease 4. The Endocrine Society guidelines suggest continuing treatment as long as symptoms persist and the patient is not planning pregnancy 7. Effects on hirsutism typically require 6-12 months to become fully apparent.
Special Populations
Adolescents: The Endocrine Society recommends COCs as first-line treatment for adolescents with PCOS when treating acne, hirsutism, or anovulatory symptoms 7. Spironolactone can be added if COCs alone are insufficient, but the same contraception and monitoring requirements apply.
Women with obesity: Spironolactone shows similar safety profiles regardless of BMI 4, but lifestyle modification and metformin should be concurrent first-line interventions 7.